Verastem Oncology Reveals First Patient Dosed With GFH375/VS-7375, A KRAS G12D (ON/OFF) Inhibitor, In A Phase 1/2 Trial In China As Part Of Collaboration With GenFleet Therapeutics

7/12/24 7:33:04 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VSTM alert in real time by email

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the first patient has been dosed in a Phase 1/2 trial in China, conducted by GenFleet Therapeutics, evaluating GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor.

GFH375/VS-7375, was selected as Verastem's lead discovery program from its collaboration with GenFleet established in 2023. GFH375/VS-7375 is an oral, potent and selective KRAS G12D dual inhibitor of ON (GTP) and OFF (GDP) states. Preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2024 demonstrated oral bioavailability across preclinical species, strong anti-tumor activity as a single agent and potency against intracranial tumor models suggesting the potential to treat brain metastases.

Get the next $VSTM alert in real time by email

Date	Price Target	Rating	Analyst
9/30/2024	$13.00	Buy	Guggenheim
11/21/2023	$27.00	Buy	BTIG Research
9/27/2023	$21.00	Buy	B. Riley Securities
6/15/2023	$24.00 → $36.00	Neutral → Buy	Mizuho
9/7/2022	$6.00	Buy	Alliance Global Partners
4/29/2022	$6.00 → $5.00	Overweight	Cantor Fitzgerald
4/14/2022	$5.00	Outperform	RBC Capital Mkts
3/9/2022	$6.00	Buy	Truist

Verastem Oncology Reveals First Patient Dosed With GFH375/VS-7375, A KRAS G12D (ON/OFF) Inhibitor, In A Phase 1/2 Trial In China As Part Of Collaboration With GenFleet Therapeutics

Chat with this insight

Recent Analyst Ratings for $VSTM

$VSTM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Paterson Dan sold $3,118 worth of shares (812 units at $3.84), decreasing direct ownership by 0.35% to 231,576 units (SEC Form 4)

Chief Financial Officer Calkins Daniel sold $17 worth of shares (6 units at $2.86), decreasing direct ownership by 0.01% to 47,461 units (SEC Form 4)

Chief Financial Officer Calkins Daniel sold $257 worth of shares (93 units at $2.76), decreasing direct ownership by 0.20% to 47,467 units (SEC Form 4)

$VSTM SEC Filings

SEC Form SCHEDULE 13G filed by Verastem Inc.

SEC Form 10-Q filed by Verastem Inc.

Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$VSTM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Verastem with a new price target

BTIG Research resumed coverage on Verastem with a new price target

B. Riley Securities initiated coverage on Verastem with a new price target

$VSTM Press Releases

Fastest customizable press release news feed in the world

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

$VSTM Market Insights

Live Market Insights

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Verastem shares are trading lower after the company announced it priced its $55 million public offering of 13,333,334 of its common stocks and accompanying warrants at $3.00 per share and accompanying warrant.

Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

$VSTM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

$VSTM Financials

Live finance-specific insights

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

$VSTM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Verastem Inc.

Amendment: SEC Form SC 13G/A filed by Verastem Inc.

SEC Form SC 13G filed by Verastem Inc.

$VSTM Leadership Updates

Live Leadership Updates

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

Recent Analyst Ratings for
$VSTM

$VSTM
Insider Trading

$VSTM
SEC Filings

$VSTM
Analyst Ratings

$VSTM
Press Releases

$VSTM
Market Insights

$VSTM
Insider Purchases

$VSTM
Financials

$VSTM
Large Ownership Changes

$VSTM
Leadership Updates